No price history available.

Based on consensus from external analysts. Not Kvantra's opinion.

SK bioscience Co.,Ltd. is a pharmaceutical firm focused on the discovery, development, production, and worldwide commercialization of vaccines and other biopharmaceutical products. Its current range of marketed vaccines includes Skycellflu, a cell-cultured influenza vaccine, along with its pre-filled syringe version, Skycellflu 4-ga. The company also provides pneumococcal vaccines for both adults and children, Skyzoster for shingles, and Sky Baricella, designed to prevent chickenpox in pediatric patients. Beyond its existing portfolio, SK bioscience maintains an active research and development pipeline. Several candidates have completed Phase 2 clinical trials, including an oral rotavirus vaccine, a cervical cancer vaccine, and a low-cost pneumococcal vaccine. A distinct rotavirus vaccine is currently in Phase 3 trials in Africa, while a next-generation pneumococcal vaccine is undergoing Phase 2 trials in the United States. Other projects in development include a typhoid conjugate vaccine and a COVID-19 vaccine, which is progressing through Phase 1 and Phase 1/2 clinical studies. The company was established in 2018 and is headquartered in Seongnam-si, South Korea.

• GH Research PLC
• Pell Bio-Med Technology Co., Ltd.
• Anhui Anke Biotechnology (Group) Co., Ltd.
• Zenas BioPharma, Inc.
• Ocular Therapeutix, Inc.
• Nanobiotix S.A.
• Aurinia Pharmaceuticals Inc.
• Taysha Gene Therapies, Inc.